Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPRINT: Sasanlimab and Immuno-PET in NSCLC
NCT06218069Phase 3Not yet recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Feb 2025
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, open-label trial of sasanlimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Number of participants with successful completion of curative surgery within 42 days after start of subcutaneous sasanlimab as neo-adjuvant treatment, The number of CTC grade >=3 toxicity related to subcutaneous sasanlimab as neo-adjuvant treatment at 2 years and 1 more. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
sasanlimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06218069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06218069.